COVID-19-Vaccine Market as a New Segment of the Global Vaccine Market-Reference-Cited by-同舟云学术

COVID-19-Vaccine Market as a New Segment of the Global Vaccine Market

Published:2021-08-13 Issue:2 Volume:2021 Page:178-190
ISSN:2500-3372
Container-title:Bulletin of Kemerovo State University. Series: Political, Sociological and Economic sciences
language:en
Short-container-title:

Author:

Goroshko Nadezhda¹,Patsala Sergey¹,Emelyanova Elena²

Affiliation:

1. Novosibirsk State Pedagogical University

2. Novosibirsk State Medical University

Abstract

The vaccine market is one of the most attractive and fast-growing segments of the global pharmaceutical market. The increasing interest in the development and creation of new vaccines caused a significant influx of investment in research activities, which did not slow down the impact on the further development of the market. The present research featured the global market for COVID-19 vaccines. The research objective was to assess the state of the COVID vaccine market as a new segment of the global vaccine market. The work uses statistical materials of the World Health Organization, the International Federation of Pharmaceutical Manufacturers and Associations, Statista, Rosstat, and Rospotrebnadzor, as well as methods of general logical, analytical, statistical, and empirical analyses. The demands for the global COVID-19 vaccine market are currently enormous, and the global demand for COVID-19 vaccines can range from 10 to 14 billion doses per year, depending on the desired level of coverage and the need for re-vaccination. The current leading manufacturers of vaccines against COVID-19 are Pfizer (USA) / BioNTech (Germany), Sinovac Biotech (China), AstraZeneca (UK), Moderna (USA), and Sinopharm (China). In terms of production volumes, they are significantly inferior to N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology (Russia). The prevalence of World Health Organization-approved vaccines differs by country: (1) Vaxzevria vaccine (AstraZeneca) was approved in 101 countries, (2) Pfizer / BioNTech – in 85 countries, (3) Moderna – in 46 countries, (4) Sinopharm vaccines – 42 countries, (5) Janssen (Johnson & Johnson) – in 41 countries, (6) Covishield (Serum Institute of India) – in 40 countries. As of May 20, 2021, the Russian Sputnik V was registered in 68 countries. For all manufacturers, the expansion of production provokes the same problems, which are mostly connected with the supply of culture media, filters, disposable consumables, and equipment, especially during peak demand.

Publisher

Kemerovo State University

Subject

Applied Mathematics,General Mathematics

Reference20 articles.

1. Ortega-Sanchez I. R., Molinari N.-A. M., Fairbrother G., Szilagyi P. G., Edwards K. M., Griffin M. R., Cassedy A., Poehling  K. A., Bridges C., Staat M. A. Indirect, out-of-pocket and medical costs from influenza-related illness in young children // Vaccine. 2012. Vol. 30. Iss. 28. P. 4175–4181. DOI: 10.1016/j.vaccine.2012.04.057, Ortega-Sanchez I. R., Molinari N.-A. M., Fairbrother G., Szilagyi P. G., Edwards K. M., Griffin M. R., Cassedy A., Poehling K. A., Bridges C., Staat M. A. Indirect, out-of-pocket and medical costs from influenza-related illness in young children. Vaccine, 2012, 30(28): 4175–4181. DOI: 10.1016/j.vaccine.2012.04.057

2. Андрианова Е. П., Приказчикова Ю. В. О современных тенденциях развития мирового и российского рынка вакцин // Современные научные исследования и инновации. 2016. № 5. C. 163–166., Andrianova E. P., Prikazchikova Yu. V. About current trends of the global and Russian vaccine markets' development. Sovremennye nauchnye issledovaniia i innovatsii, 2016, (5): 163–166. (In Russ.)

3. Акимова Ю. И., Проценко М. В. Обзор российского рынка вакцин: специфика, динамика развития, перспективы // Современная организация лекарственного обеспечения. 2013. № 3. С. 10–22., Akimova Yu. I., Protsenko M. V. The Russian market of vaccines: specificity, the dynamics of development and prospects. Sovremennaia organizatsiia lekarstvennogo obespecheniia, 2013, (3): 10–22. (In Russ.)

4. Трухин В. П., Наркевич И. А., Басакина И. И., Барабанова А. И. Маркетинговый анализ российского рынка иммунобиологических лекарственных препаратов в рамках сегмента вакцин // Медицинский вестник Башкортостана. 2019. Т. 14. № 3. С. 47–50., Trukhin V. P., Narkevich I. A., Basakina I. I., Barabanova A. I. Marketing analysis of the Russian immunobiological medicines market within the framework of vaccines. Medicinskij vestnik Bashkortostana, 2019, 14(3): 47–50. (In Russ.)

5. Li T., Zhang T., Gu Y., Li S., Xia N. Current progress and challenges in the design and development of a successful COVID-19 vaccine // Fundamental Research. 2021. Vol. 1. Iss. 2. P. 139–150. DOI: 10.1016/j.fmre.2021.01.011, Li T., Zhang T., Gu Y., Li S., Xia N. Current progress and challenges in the design and development of a successful COVID-19 vaccine. Fundamental Research, 2021, 1(2): 139–150. DOI: 10.1016/j.fmre.2021.01.011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VACCINES AS A PRODUCT OF INDUSTRIAL BIOTECHNOLOGIES AND A SPECIAL COMMODITY IN THE INTERNATIONAL BIOPHARMACEUTICALS MARKET;International Trade and Trade Policy;2023-10-15

2. Russian vaccines against COVID-19: their characteristics, efficacy and safety;Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH);2022-11-18